Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Sevabertinib with Dabigatran and Rosuvastatin
NCT06329895Phase 1Completed
- Sponsor
- Bayer
- Start
- Mar 2024
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sevabertinib in non-small cell lung cancer (NSCLC), sponsored by Bayer. Primary endpoints: Maximum observed concentration of unconjugated dabigatran at Day 9, Area under the curve of unconjugated dabigatran at Day 9 and 2 more. Started Mar 2024; status: completed.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06329895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06329895.